Covid19
Conditions
Keywords
Immunohematology, Blood group, COVID-19
Brief summary
This is a hospital-based retrospective cohort study and the Immunohematologic characteristics of COVID-19 patients will be investigated systematically.
Detailed description
This is a hospital-based retrospective cohort study and the Immunohematologic characteristics of COVID-19 patients will be investigated systematically. In this study, we will seek to understand the association between SARS-CoV-2 infection and blood groups and explore the Anti-A and Anti-B effects in COVID-19 patients with graded severity. We will analyze the transfusion requirement and the clinical recurrences of COVID-19 patients. The discrepancy of blood group phenotypes in COVID-19 patients with graded severity will be also analyzed on the molecular level. This retrospective cohort study was conducted using electronic health recording data in Tongji Hospital. The clinical characteristics for all eligible patients will be retrieved. The records will be verified to avoid possible bias. Data collection was carried out independently by two investigators and reviewed by two different investigators.
Interventions
None listed
Sponsors
National Institutes of Health (NIH)
Henan University of Science and Technology
LI YAN
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* The patients who were diagnosed with COVID-19 following the WHO interim guidelines (https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected. 2020.)
Exclusion criteria
* Male or female patients \<18 years of age
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ABO and Rh distribution | 1 year | ABO and Rh phenotype distribution refers to the phenotype frequency of the ABO and Rh subtypes in severe and non-severe COVID-19 patients |
| ABO antibody titers | 1 year | ABO antibody titers refers to both anti-A and anti-B antibodies in severe and non-severe COVID-19 patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Leukocyte and neutrophil counts | 1 year | Leukocyte and neutrophil counts refer to the number of Leukocyte and neutrophil COVID-19 hospitalized patients with graded severity |
| Transfusion incidence | 1 year | Transfusion incidence refers to the number of COVID-19 hospitalized patients who received transfusion |
| Polymorphism of ABO blood group | 1 year | Polymorphism of ABO blood group refers to the variations and alleles of the ABO gene in COVID-19 patients |
| outcomes of SARS-CoV-2 infection | 1 year | outcomes of SARS-CoV-2 infection refer to the intubation and death in SARS-CoV-2 infected patients |
| Patients with coagulopathy | 1 year | Patients with coagulopathy refers to patients hospitalized with Covid-19 to develop coagulopathy |
Countries
China
Outcome results
None listed